tbuckley/cabot-search huggingface dataset:
Genetic Variant of CXCR1 (rs2234671) Associates with Clinical Outcome in Perihilar Cholangiocarcinoma
Authors: Isabella Lurje, Zoltan Czigany, Jan Bednarsch, Nadine Therese Gaisa, Edgar Dahl, Ruth Knüchel, Hannah Miller, Tom Florian Ulmer, Pavel Strnad, Christian Trautwein, Frank Tacke, Ulf Peter Neumann, Georg Lurje
Journal: Liver Cancer (2022)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Perihilar cholangiocarcinoma (pCCA) is a rare primary liver malignancy. Even in patients amenable to surgery, outcomes are often dismal. Here, we aimed to identify prognostic markers for patient outcomes by analyzing functionally relevant single-nucleotide polymorphisms (SNPs) in genes with a role in tumor inflammation and angiogenesis. We analyzed 11 polymorphisms in the inflammation-angiogenesis axis (&lt;i&gt;VEGF, EGF, EGFR, IL-1b, IL-6, CXCL8 (IL-8), IL-10, CXCR1, HIF1A&lt;/i&gt;, and &lt;i&gt;COX2&lt;/i&gt; genes) for their prediction of tumor recurrence and survival in pCCA patients undergoing surgery in a curative intent. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; Samples were obtained from 111 patients with pCCA undergoing liver resection in curative intent. DNA was extracted and analyzed using polymerase chain reaction-restriction fragment length polymorphism protocols and correlated with patients’ outcomes. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Out of the assessed variants, only the &lt;i&gt;CXCR1&lt;/i&gt; (also: interleukin-8-receptor alpha – &lt;i&gt;IL-8RA&lt;/i&gt;) +860C&amp;#x3e;G heterozygous polymorphism (rs2234671) was associated with decreased disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS) (18/111 (16.2%), median DFS 14 months, log-rank &lt;i&gt;p&lt;/i&gt; = 0.007; median CSS 31 months, log-rank &lt;i&gt;p&lt;/i&gt; = 0.007; and median OS 6 months, log-rank &lt;i&gt;p&lt;/i&gt; = 0.002), compared to the GG genotype (92/111 (82.9%), median DFS 55 months, median CSS 63 months, and median OS 33 months). In the multivariate analysis, +860C&amp;#x3e;G remained an independent prognostic factor for DFS (adjusted &lt;i&gt;p&lt;/i&gt; = 0.008), CSS (adjusted &lt;i&gt;p&lt;/i&gt; = 0.001), and OS (adjusted &lt;i&gt;p&lt;/i&gt; = 0.001). &lt;b&gt;&lt;i&gt;Conclusion:&lt;/i&gt;&lt;/b&gt; Genetic variant of &lt;i&gt;CXCR1&lt;/i&gt; +860C&amp;#x3e;G may serve as a molecular marker for DFS, CSS, and OS in patients undergoing curative-intent surgery for pCCA, indicating that the analysis of SNPs in genes involved in immune-mediated angiogenesis may help to identify patient subgroups at high risk for dismal oncological and overall outcome.
Machine learning approach for culprit drug identification based on drug-specific interferon-gamma releasing cells and clinical parameters in non-immediate drug hypersensitivity
Authors: Yuda Chongpison, Pawinee Rerknimitr, Sira Srisawatra, Pungjai Mongkolpathumrat, Supranee Buranapraditkul, Pattarawat Thantiworasit, Leena Chularojanamontri, Yuttana Srinoulprasert, Ticha Rerkpattanapipat, Kumutnart Chanprapaph, Wareeporn Disphanurat, Panlop Chakkavittumrong, Napatra Tovanabutra, Chutika Srisuttiyakorn, Chonlaphat Sukasem, Papapit Tuchinda, Padcha Pongcharoen, Jettanong Klaewsongkram
Journal: Journal of Allergy and Clinical Immunology (2022)
Endoscopic submucosal dissection of poorly differentiated carcinoma mimicking adenoid-cystic carcinoma of the esophagus
Authors: Fabio De Vincentis, Roberta Maselli, Mario Brancaccio, Alessandro Mussetto
Journal: Endoscopy (2022)

Corrected by: Correction: Endoscopic submucosal dissection of poorly differentiated carcinoma mimicking adenoid-cystic carcinoma of the esophagus Endoscopy 2022; 54(11): C19-C19DOI: 10.1055/a-1823-2928
Covid-19: Lower vaccination rates partly explain higher death rates among minority ethnic groups
Authors: Ingrid Torjesen
Journal: BMJ (2022)

Covid-19: Lower vaccination rates partly explain higher death rates among minority ethnic groups Ingrid TorjesenDeath rates from covid-19 remain higher for most minority ethnic groups compared with people identifying as white British, and some of that disparity is because of their lower uptake of vaccinations, show data from the Office for National Statistics (ONS). 1
Book Reviews
Journal: Allergy (1984)

Book reviewed in this article: Lichtenstein, L. M. &amp; Fauci, A. S. : Current therapy in allergy and immunology 1983–1984 Ricci, M. &amp; Marone, G. (eds.): Progress in clinical immunology: The role of chemical mediators and cellular interactions Middleton, E., Reed, C. E. &amp; Ellis, E. F. (eds.): Allergy. Principles and practice
A light-driven dual-nanotransformer with deep tumor penetration for efficient chemo-immunotherapy
Authors: Jiahui Peng, Fangman Chen, Yulu Liu, Fan Zhang, Lei Cao, Qiannan You, Dian Yang, Zhimin Chang, Mingfeng Ge, Li Li, Zheng Wang, Qian Mei, Dan Shao, Meiwan Chen, Wen-Fei Dong
Journal: Theranostics (2022)

Designing a transformable nanosystem with improved tumor accumulation and penetration by tuning multiple physicochemical properties remains a challenge. Here, a near-infrared (NIR) light-driven nanosystem with size and charge dual-transformation for deep tumor penetration is developed. Methods: The core-shell nanotransformer is realized by integrating diselenide-bridged mesoporous organosilica nanoparticles as a reactive oxygen species (ROS)-responsive core with an indocyanine green (ICG)-hybrid N-isopropyl acrylamide layer as a thermosensitive shell. After loading doxorubicin (DOX), negatively charged nanomedicine prevents DOX leakage, rendering prolonged blood circulation time and high tumor accumulation. Results: Upon NIR light irradiation, mild photothermal effects facilitate the dissociation of the thermosensitive shell to achieve negative-to-positive charge reversal. Meanwhile, ICG-generated ROS cleave the diselenide bond of the organosilica core, resulting in rapid matrix degradation that produces DOX-containing smaller fragments. Such a light-driven dual-transformable nanomedicine simultaneously promotes deep tumor penetration and implements sufficient chemotherapy, along with evoking robust immunogenic cell death effects in vitro and in vivo. With the combination of a programmed cell death protein-1 (PD-1) checkpoint blockade, the nanotransformer remarkably blocks primary tumor growth and pulmonary metastasis of breast cancer with low systemic toxicity. Conclusions: This study develops a promising strategy to realize high tumor accumulation and deep penetration of light-transformable nanomedicine for efficient and safe chemo-immunotherapy.
Kompendium der topischen Gehirn- und Rückenmarksdiagnostik. Kurzgefasste Anleitung zur klinischen Lokalisation der Erkrankungen und Verletzungen der Nervenzentren.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
COVID-19 and the Common Cold—Preexisting Coronavirus Antibodies May Hinder SARS-CoV-2 Immunity
Authors: Jennifer Abbasi
Journal: JAMA (2022)

our seasonal coronaviruses-2 of which are betacoronaviruses, like SARS-CoV-2-cause about 30% of common colds.Instead of helping to fight off COVID-19, antibodies to these pathogens may interfere with the SARS-CoV-2 immune response, a recent study of health care workers suggests.Although these preexisting antibodies are ubiquitous, individuals' varying levels of them might factor into the broad spectrum of responses to the novel coronavirus, which range from immunity against infection all the way to severe respiratory distress and death. The BackstoryAlmost since the COVID-19 pandemic began, scientists have investigated how immunity to the seasonal coronaviruses might influence infections with SARS-CoV-2, a new but related virus.A number of reports now show that preexisting common cold coronavirus antibodies are active in SARS-CoV-2 infections, according to Patrick Wilson, PhD, a professor of pediatrics and a scientist in the Gale and Ira Drukier Institute for Children's Health at Weill Cornell Medicine, who was not involved with the new study.Last year, Wilson and colleagues at the University of Chicago, where he was based at the time, found that people with severe acute SARS-CoV-2 infections had substantial numbers of antibody-secreting B cells that reacted to common cold coronaviruses.The cells had highly mutated and variable genes, likely indicating that they predated the patients' novel coronavirus infections.As for an influence on COVID-19, one early 2021 University of Pennsylvania study concluded that preexisting antibodies to common cold coronaviruses did not correlate with SARS-CoV-2 protection.But the overall findings have been inconsistent.Taken together, it's hard to say which way they lean because the studies' scope, participants, and methods have varied, according to Maureen McGargill, PhD, the senior author of the recent health
UREA AND UREMIA
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hepatitis C in human immunodeficiency virus-coinfected patients: Increased variability in the hypervariable envelope coding domain
Authors: K Sherman
Journal: Hepatology (1996)

Patients coinfected with the hepatitis C virus (HCV) and the human immunodeficiency virus (HIV) were studied with regard to nucleotide sequence variability in the E2/NS1 first hypervariable region of the HCV genome. The nucleotide variability within individual patients was compared to patients infected only with HCV. The proportion of predicted synonymous and nonsynonymous amino acid changes, and the relationship to putative high-antigenicity sites, were evaluated in the hypervariable envelope domain. Ninety-one clones from 10 patients with HCV/HIV coinfection were sequenced, following polymerase chain reaction (PCR) amplification of the hypervariable region. The control HCV group included 53 clones from 7 patients. Sequence analysis encompassed the region coding for amino acids 384 to 414. Consensus sequences from each patient were used as the internal standard for nonsynonymous amino acid codon variability. Cumulative proportional comparison at each amino acid site revealed increased variability in HCV RNA from patients with HCV/HIV coinfection versus HCV alone (P < .05). The greatest variability was observed at amino acids 386, 397, 400, 402, 405, 407, and 414, with > l0 percent clonal variation at these sites. Jameson-Wolf plots were used to predict putative high-antigenicity domains. Nonsynonymous clonal variation resulted in alteration of putative antigenic sites within the hypervariable region. All clones had at least one high-probability site. Clones with unique predicted antigenic domains were observed more frequently in HIV/HCV coinfected patients, and, independent of viral titer, were consistent with increased sequence variability. These data suggest an accumulation of envelope variants in the HCV/HIV coinfected patients, which could be related to ineffective viral clearance, and may help explain prior reports of interferon (IFN) resistance in this patient group.
A Perfect Pair: Stabilized Black Phosphorous Nanosheets Engineering with Antimicrobial Peptides for Robust Multidrug Resistant Bacteria Eradication
Authors: Jintao Fu, Ting Liu, Xiaoqian Feng, Yixian Zhou, Minglong Chen, Wenhao Wang, Yiting Zhao, Chao Lu, Guilan Quan, Jianfeng Cai, Xin Pan, Chuanbin Wu
Journal: Advanced Healthcare Materials (2022)

Abstract Black phosphorus (BP) nanosheets emerged as promising 2D nanomaterial that have been applied to eradicate antibiotic‐resistant bacteria. However, their applications are limited by intrinsic ambient instability. Here, the ε ‐poly‐ l ‐lysine ( ε ‐PL)‐engineered BP nanosheets are constructed via simple electrostatic interaction to cater the demand for passivating BP with amplified antibacterial activity. The dual drug‐delivery complex named BP@ε‐PL can closely anchor onto the surface of bacteria, leading to membrane disintegration. Subsequently, in situ hyperthermia generated by BP under near‐infrared (NIR) irradiation can precisely eradicate pathogenic bacteria. In vitro antibacterial studies verify the rapid disinfection ability of BP@ ε ‐PL against Methicillin‐resistant Staphylococcus aureus (MRSA) within 15 min. Moreover, ε ‐PL can serve as an effective protector to avoid chemical degradation of bare BP. The in vivo antibacterial study shows that a 99.4% antibacterial rate in a MRSA skin infection model is achieved, which is accompanied by negligible toxicity. In conclusion, this work not merely provides a new conjecture for protecting the BP, but also opens a novel window for synergistic antibiotic‐resistant bacteria therapy based on antimicrobial peptides and 2D photothermal nanomaterial.
Obituary Listing
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RISK ASSESSMENT FOR CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICES (LVAD): DOES THE DESTINATION THERAPY RISK SCORE WORK? AN ANALYSIS OF OVER 600 PATIENTS
Authors: Jeffrey Teuteberg, Joseph G. Rogers, Soon J. Park, Gregory A. Ewald, Antone J. Tatooles, Katherine Lietz, Leslie W. Miller, Robert L. Kormos, Kartik S. Sundareswaran, David J. Farrar, Mark S. Slaughter
Journal: Journal of the American College of Cardiology (2011)
LIGHT Deficiency Protects Against Esophageal Remodeling In A Murine Model Of Chronic Eosinophilic Esophagitis
Authors: Mario Manresa, Haruka Miki, Jacqueline Miller, Rinkesh Gupta, Rana Herro, Seema Aceves, Michael Croft
Journal: Journal of Allergy and Clinical Immunology (2022)
Textbook of Immunopathology
Authors: Cecil A. Krakower
Journal: JAMA (1969)

Recent advances in immunology bearing on human diseases have been introduced to a limited degree into current clinical textbooks. For more extensive consideration of one or another facet of these diseases, one has had to resort to special review articles, monographs, or symposia. The editors are, therefore, to be commended for bringing such vast amounts of information into one text. There are 75 contributors, most of whom are well-known experts in their field. The text is divided into two sections. In the first, there is brief coverage of the general principles of immunology. These include the mechanisms of immunization, the structure of antibodies, the complement system and immunologic unresponsiveness (tolerance). This is followed by a discussion of pathogenic immune mechanisms such as anaphylaxis, cell and tissue damage through antigen-antibody complexes (Arthur phenomenon, serum sickness), and delayed hypersensitivity. The rest of this section deals with selected experimental immune diseases in which
Hierarchical graph attention network for miRNA-disease association prediction
Authors: Zhengwei Li, Tangbo Zhong, Deshuang Huang, Zhu-Hong You, Ru Nie
Journal: Molecular Therapy (2022)

Many biological studies show that the mutation and abnormal expression of microRNAs (miRNAs) could cause a variety of diseases. As an important biomarker for disease diagnosis, miRNA is helpful to understand pathogenesis, and could promote the identification, diagnosis and treatment of diseases. However, the pathogenic mechanism how miRNAs affect these diseases has not been fully understood. Therefore, predicting the potential miRNA-disease associations is of great importance for the development of clinical medicine and drug research. In this study, we proposed a novel deep learning model based on hierarchical graph attention network for predicting miRNA-disease associations (HGANMDA). Firstly, we constructed a miRNA-disease-lncRNA heterogeneous graph based on known miRNA-disease associations, miRNA-lncRNA associations and disease-lncRNA associations. Secondly, the node-layer attention was applied to learn the importance of neighbor nodes based on different meta-paths. Thirdly, the semantic-layer attention was applied to learn the importance of different meta-paths. Finally, a bilinear decoder was employed to reconstruct the connections between miRNAs and diseases. The extensive experimental results indicated that our model achieved good performance and satisfactory results in predicting miRNA-disease associations.
Books Received
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Estimates of the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe from 2015 to 2017: an analysis of data from the cross-sectional Population-based HIV Impact Assessment surveys
Authors: Chloe A Teasdale, Rebecca Zimba, Elaine J Abrams, Karampreet Sachathep, Felix Ndagije, Harriet Nuwagaba-Biribonwoha, Godfrey Musuka, Owen Mugurungi, Limpho Maile, Mary Mahy, Andrea Low
Journal: The Lancet HIV (2022)
Abortion
Authors: Curtis E. Harris
Journal: JAMA (1990)

<h3>To the Editor.—</h3> The highly emotional story by Dr Furth<sup>1</sup>should not go unbalanced. She makes the plea that illegal abortions should not be allowed because of her personal experience with an abortionist. I believe in a vigorous prosecution of illegal abortions regardless of the laws of the nation. Abortion is not a safe procedure even in the hands of physicians. I am aware of two deaths directly related to<i>legal</i>abortions in my city during this last year. Abortion is certainly less safe in the hands of the "quack" abortionist who has no idea what he or she is doing. A physician (or nonphysician) who performs an abortion that causes severe complications or death should be held liable either by civil or criminal penalty. Rather than focusing on the rare case of an illegal abortion that causes death, we should enforce laws that regulate abortion. It is my